MX2022011238A - Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. - Google Patents

Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.

Info

Publication number
MX2022011238A
MX2022011238A MX2022011238A MX2022011238A MX2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A
Authority
MX
Mexico
Prior art keywords
combinations
probenecid
valproic acid
beta
lactam compounds
Prior art date
Application number
MX2022011238A
Other languages
English (en)
Inventor
Michael Dunne
Original Assignee
Iterum Therapeutics International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterum Therapeutics International Ltd filed Critical Iterum Therapeutics International Ltd
Publication of MX2022011238A publication Critical patent/MX2022011238A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se relaciona con combinaciones de ácido valproico o una sal farmacéuticamente aceptable del mismo, un compuesto ß-lactámico o una sal farmacéuticamente aceptable del mismo y probenecid o una sal farmacéuticamente aceptable del mismo; la presente descripción también se relaciona con métodos para tratar o prevenir una enfermedad usando las combinaciones.
MX2022011238A 2020-03-11 2021-03-11 Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. MX2022011238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062987963P 2020-03-11 2020-03-11
PCT/EP2021/056210 WO2021180857A1 (en) 2020-03-11 2021-03-11 Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011238A true MX2022011238A (es) 2022-10-07

Family

ID=74871410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011238A MX2022011238A (es) 2020-03-11 2021-03-11 Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.

Country Status (10)

Country Link
US (1) US20210283112A1 (es)
EP (1) EP4117645A1 (es)
JP (1) JP2023517919A (es)
KR (1) KR20220152261A (es)
CN (1) CN115190797A (es)
AU (1) AU2021235058A1 (es)
BR (1) BR112022015925A2 (es)
CA (1) CA3169900A1 (es)
MX (1) MX2022011238A (es)
WO (1) WO2021180857A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
RU2499592C2 (ru) * 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
EP3427729A1 (en) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof

Also Published As

Publication number Publication date
AU2021235058A1 (en) 2022-09-01
BR112022015925A2 (pt) 2022-10-04
CN115190797A (zh) 2022-10-14
JP2023517919A (ja) 2023-04-27
EP4117645A1 (en) 2023-01-18
KR20220152261A (ko) 2022-11-15
CA3169900A1 (en) 2021-09-16
US20210283112A1 (en) 2021-09-16
WO2021180857A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CR20220354A (es) Inhibidores de egfr
MX2022015207A (es) Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2021011606A (es) Compuestos dirigidos a prmt5.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021012105A (es) Compuestos de pirrol.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2021013531A (es) Inhibidores de cdk.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2023009037A (es) Compuesto de pirimidopirano.
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
MX2021009755A (es) Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021009717A (es) Sulfonamidas biciclicas.
MX2019008728A (es) Compuestos de amida y su uso.
MX2022011238A (es) Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.
JOP20210319A1 (ar) مركبات بيروليدين